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Distinct ex vivo susceptibility of B-cell subsets to epstein-barr
virus infection according to differentiation status and tissue
origin
Abstract
Epstein-Barr virus (EBV) uses tonsils as the portal of entry to establish persistent infection. EBV is
found in various B-cell subsets in tonsils but exclusively in memory B cells in peripheral blood. The in
vitro susceptibilities of B-cell subsets to EBV infection have been studied solely qualitatively. In this
work, we examined quantitatively the in vitro susceptibilities of various B-cell subsets from different
tissue origins to EBV infection. First, we established a centrifugation-based inoculation protocol
(spinoculation) that resulted in a significantly increased proportion of infected cells compared to that
obtained by conventional inoculation, enabling a detailed susceptibility analysis. Importantly, B-cell
infection occurred via the known EBV receptors and infected cells showed EBV mRNA expression
patterns similar to those observed after conventional inoculation, validating our approach. Tonsillar
naïve and memory B cells were infected ex vivo at similar frequencies. In contrast, memory B cells
from blood, which represent B cells from various lymphoid tissues, were infected at lower frequencies
than their naïve counterparts. Immunoglobulin A (IgA)-positive or IgG-positive tonsillar memory B
cells were significantly more susceptible to EBV infection than IgM-positive counterparts. Memory B
cells were transformed with lower efficiency than naïve B cells. This result was paralleled by lower
proliferation rates. In summary, these data suggest that EBV exploits the B-cell differentiation status and
tissue origin to establish persistent infection.
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Epstein-Barr virus (EBV) uses tonsils as the portal of entry to establish persistent infection. EBV is found
in various B-cell subsets in tonsils but exclusively in memory B cells in peripheral blood. The in vitro
susceptibilities of B-cell subsets to EBV infection have been studied solely qualitatively. In this work, we
examined quantitatively the in vitro susceptibilities of various B-cell subsets from different tissue origins to
EBV infection. First, we established a centrifugation-based inoculation protocol (spinoculation) that resulted
in a significantly increased proportion of infected cells compared to that obtained by conventional inoculation,
enabling a detailed susceptibility analysis. Importantly, B-cell infection occurred via the known EBV receptors
and infected cells showed EBV mRNA expression patterns similar to those observed after conventional
inoculation, validating our approach. Tonsillar naı¨ve and memory B cells were infected ex vivo at similar
frequencies. In contrast, memory B cells from blood, which represent B cells from various lymphoid tissues,
were infected at lower frequencies than their naı¨ve counterparts. Immunoglobulin A (IgA)-positive or IgG-
positive tonsillar memory B cells were significantly more susceptible to EBV infection than IgM-positive
counterparts. Memory B cells were transformed with lower efficiency than naı¨ve B cells. This result was
paralleled by lower proliferation rates. In summary, these data suggest that EBV exploits the B-cell differen-
tiation status and tissue origin to establish persistent infection.
Epstein-Barr virus (EBV) infects over 90% of the world’s
population and establishes life-long persistence in the memory
B cells of the infected host (32). In vitro, EBV can transform
and immortalize B cells to generate lymphoblastoid cell lines
(LCLs) (19). That characteristic points at the potential neo-
plastic role of EBV in several tumors of B-cell origin in hu-
mans, including Burkitt’s lymphoma, Hodgkin’s disease, and
posttransplant lymphoproliferative disease (8, 21).
The mucosal lymphoid tissues of the Waldeyer’s ring, includ-
ing tonsils, act as the original site of EBV infection and the
reservoir for the virus where B-cell infection initiates during
infectious mononucleosis (2–4, 24, 28). EBV is detected in
both naı¨ve and memory B cells when infected tonsillar tissue is
examined (3). By contrast, EBV is found exclusively in memory
B cells when peripheral blood is examined (2, 18). Notably,
EBV-infected naı¨ve B cells isolated from tonsils express a
lymphoblastoid phenotype corresponding to latent EBV genes,
whereas EBV-infected memory B cells from tonsils express a
more restricted pattern (3). In contrast, the EBV-infected
memory B cells isolated from the peripheral blood display a
very restricted pattern of EBV latent gene expression, in which
no latent EBV genes, with the possible exception of LMP2, are
expressed (3). Thus, B cells from distinct compartments show
different EBV infection and gene expression patterns. Notably,
the cited data from in vivo studies are purely descriptive and no
data on the relative EBV susceptibilities of naı¨ve and memory
B cells from different compartments are yet available. In par-
ticular, we do not know to what extent the pool of EBV-
infected memory B cells in the tonsils is derived from naı¨ve
EBV-infected B cells that have gone through a germinal-center
reaction or how the pools of infected cells are influenced by
distinct proliferation rates of naı¨ve and memory B cells follow-
ing EBV infection. Also, given the different EBV gene expres-
sion patterns in naı¨ve and memory tonsillar B cells, EBV-
infected cells from different subsets may be subjected to
differential recognition by EBV-specific immune responses,
which in turn may impact the survival and thus the frequencies
of these cells. Information on the relative susceptibilities of the
various B cells and the subsequent phenotypic changes would
be highly desired for a detailed understanding of EBV patho-
genesis.
There are only limited detailed quantitative data available
about the susceptibilities to EBV infection of distinct B-cell
subsets. It appears that EBV infects various subsets of B cells
from tonsils, adenoids, or peripheral blood in vitro (3, 6, 11,
15). In very early studies, the general susceptibility of B cells to
EBV infection in vitro was demonstrated by assessing trans-
formation rates of nonseparated (6) or isolated (15) B cells.
Transformation, however, provides only indirect information
about EBV infectivity and does not take into account the
proliferation and apoptosis rates of EBV-infected B-cell sub-
sets. More recent studies isolated tonsillar or adenoidal B cells
on the basis of CD10, CD77, and/or surface immunoglobulin
isotype expression (3, 11). Nowadays, memory B cells can be
more accurately identified thanks to the specific memory B-cell
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marker CD27 (20, 41). Most importantly, published work on
the in vitro infection of B-cell subsets has addressed the issue
of susceptibility to EBV infection only qualitatively, and the
efficiencies of infection of B-cell subsets from distinct tissues
have not been studied in detail. However, quantitative differ-
ences in susceptibilities of B cells to EBV infection may de-
pend on the tissue origin, and the elucidation of these differ-
ences will give further insight into EBV pathogenesis.
The aim of this work was to assess the efficiencies of EBV
infection of distinct B-cell subsets from different lymphoid
compartments and to compare the transformation behaviors of
B-cell subsets infected ex vivo with EBV. To enable these
investigations, we established a centrifugation-based inocula-
tion protocol, so-called spinoculation, using a recombinant
EBV encoding enhanced green fluorescent protein (EGFP)
(39, 40). This procedure resulted in significantly higher pro-
portions of cells infected ex vivo than conventional inoculation
and enabled us to identify EBV-infected B-cell subsets as early
as 24 h after infection and to characterize EBV-induced pro-
liferation of naı¨ve and memory B cells. Since EBV-specific
immune responses may impact the cellular infection and trans-
formation processes, we used primary cells exclusively from
EBV-naı¨ve individuals.
MATERIALS AND METHODS
Cell culture. The EBV-infected marmoset cell lines B95.8 (27) and
B95.8EBfaV-GFP (39) were maintained in RPMI 1640 medium (Gibco, Basel,
Switzerland) with 10% heat-inactivated fetal bovine serum and 1% penicillin-
streptomycin, referred to hereafter as complete medium. Primary cells were
cultivated in complete medium supplemented with 1 M sodium pyruvate and
1 nonessential amino acids (Gibco).
Isolation of mononuclear cells. Primary human mononuclear cells were iso-
lated from palatine tonsils obtained from EBV-seronegative patients undergoing
routine tonsillectomy or from blood samples taken from healthy EBV-seroneg-
ative adult donors. Tonsillar mononuclear cells (TMC) were prepared as de-
scribed previously (14). Briefly, tonsils were disintegrated with a scalpel in com-
plete medium and passed through a 70-m-pore-size cell strainer (Falcon,
Wohlen, Switzerland). For the isolation of B-cell subsets, TMC were further
purified by density gradient centrifugation with Ficoll-Hypaque (GE Healthcare,
Stockholm, Sweden). Peripheral blood mononuclear cells (PBMC) were purified
by Ficoll-Hypaque density gradient centrifugation according to the instructions
of the Ficoll-Hypaque manufacturer. The viability of primary cells, as deter-
mined by trypan blue exclusion, was99% in all preparations. The EBV serosta-
tuses of the mononuclear cell donors were determined by using the Immunodot
Mono G and Mono M kit according to the instructions of the manufacturer
(Ruwag Diagnostics, Bettlach, Switzerland). Informed consent was obtained
from subjects or parents before the study. The institutional ethics committee
approved the collection and use of clinical material.
Preparation of virus stock. B95.8 and B95.8EBfaV-GFP cells were seeded at
a density of 106 cells/ml and were stimulated to release virus by being cultured for
4 days in complete medium containing 50 ng of 12-O-tetradecanoylphorbol-13-
acetate (TPA; Sigma-Aldrich, Buchs, Switzerland)/ml. Cell suspensions were
centrifuged at 400  g for 5 min. Supernatant was passed through a 0.45-m-
pore-size cellulose acetate filter (Millipore, Zug, Switzerland) and stored at
80°C.
Infection of primary cells. EBV inoculation was done as described earlier (23).
Briefly, 1 ml of supernatant from EBV-producing cell lines was added to 2  106
cells in 1 ml of complete medium for 3 h at 37°C. For so-called conventional
inoculation, supernatants from TPA-induced EBV-producing cells lines were
used. Cell suspensions were centrifuged at 300  g for 5 min, and cells were
resuspended in fresh complete medium.
For spinoculation, EBV-containing supernatants were concentrated using a
Vivaspin 20 concentrator with polyethersulfone and a molecular weight cutoff of
1,000,000 according to the instructions of the manufacturer (Sartorius-Stedim,
Dietikon, Switzerland). Primary cells were centrifuged at 300  g for 5 min, and
the medium was completely replaced by the concentrated virus-containing su-
pernatants to a final concentration of 106 cells/ml. The cell suspensions were then
centrifuged for 1 h at 800  g at 24°C. After spinoculation, cells were washed in
phosphate-buffered saline and resuspended in fresh complete medium.
Flow cytometry. Flow cytometry was carried out on a Cytomics FC500 instru-
ment (Beckman Coulter, Nyon, Switzerland) with FlowJo software, used in
accordance with the instructions of the manufacturer (Treestar, Ashland, OR).
Antibodies. Fluorochrome-conjugated monoclonal antibodies directed against
human CD19, CD21, CD27, HLA-DR, HLA-DP, HLA-DQ, immunoglobulin D
(IgD), IgM, IgG, and IgA were purchased from BD Pharmingen (a division of
BD Biosciences, Basel, Switzerland). Unconjugated and fluorescein isothiocya-
nate (FITC)-conjugated antibodies directed against EBV gp350/220 were
purchased from Chemicon. Anti-EBV gp42 was a generous gift from L.
Hutt-Fletcher (Shreveport, LA). Rabbit antibodies against poly(ADP-ribose)
polymerase (PARP) and actin were from Cell Signaling Technology (Dan-
vers, MA).
Inhibition of EBV infection. Concentrated EBV-containing supernatants were
treated with either anti-gp350/220, anti-gp42, or a combination of the two anti-
bodies at dilutions of 1:10, 1:100, and 1:1,000 at 4°C for 1 h. TMC were infected
with the concentrated supernatants by spinoculation at 4°C to prevent virus entry
and stained with FITC-anti-gp350/220, and the amount of bound virus was
determined by flow cytometry. TMC were also analyzed for the expression of
EGFP 24 h after inoculation to evaluate the number of EBV-infected cells.
Furthermore, TMC were pretreated with anti-CD21 and anti-HLA-DR, anti-
HLA-DP, and anti-HLA-DQ at dilutions of 1:10, 1:100, and 1:1,000 for 1 h at 4°C
before inoculation with EBV by spinoculation. TMC were analyzed for EBV
infection 24 h after spinoculation by flow cytometric quantification of EGFP
expression.
Isolation of B-cell subpopulations. B cells were isolated using the B-cell
isolation kit II according to the instructions of the manufacturer (Miltenyi Bio-
tech, Bergisch Gladbach, Germany). Further separation into naı¨ve and memory
B cells was performed using the naı¨ve-B-cell isolation kit (Miltenyi Biotech) or
CD27 microbeads (Miltenyi). IgM-positive B cells were isolated by treating B
cells with phycoerythrin-conjugated anti-human IgM and separating the cells
with the PE multisort kit (Miltenyi). To obtain IgM-positive memory B cells, cells
were further subjected to CD27 microbead isolation. The purity of isolated B-cell
subsets was determined by flow cytometry using antibodies to human CD19,
CD27, IgD, IgM, IgG, and IgA for discrimination between naı¨ve and memory B
cells. Purified cell populations used for experiments were always 95% pure.
RNA extraction and quantitative real-time PCR. The preparation of total
RNA was performed using an RNeasy mini kit according to the instructions of
the manufacturer (Qiagen, Hombrechtikon, Switzerland). After DNase I diges-
tion (Ambion, Rotkreuz, Switzerland), RNA was reverse transcribed using an
Omniscript reverse transcription-PCR kit (Qiagen). Quantitative PCR for EBV
gene mRNA was performed using specific primers and probes for EBNA2,
EBNA1, EBNA3A, EBNA3C, LMP1, LMP2, or BZLF1 as described previously
(5, 23, 34). All reactions were performed on a real-time PCR machine (ABI
Prism 7700; Applied Biosystems) with TaqMan mastermix (Eurogentec, Seraing,
Belgium) by using HMBS as a housekeeping gene. Cycling conditions were as
follows: a 10-min denaturation step at 95°C was followed by 40 cycles of dena-
turation for 15 s at 95°C and annealing and synthesis for 1 min at 60°C.
Transformation assay. Transformation efficiency was assessed by a modifica-
tion of the classical protocols (35). Briefly, either unseparated TMC or isolated
naı¨ve and memory B cells were infected with B95.8 EBV by either conventional
inoculation or spinoculation. The wild-type B95.8 EBV was used to exclude
potential interference of the recombinant EBV with the transformation process.
To provide similar culture conditions for purified B cells and mononuclear cells,
we added B-cell-depleted TMC as a feeder layer for ex vivo EBV-infected naı¨ve
and memory B cells immediately after spinoculation (29). One half of the me-
dium was changed every 3 days for 4 weeks in all wells initially used.
Distributions of naı¨ve and memory B cells were evaluated by flow cytometry 1,
2, 3, and 4 weeks after infection. After 4 weeks, wells still showing proliferation
were suggested to contain transformed B cells (35). At that time, the proportion
of B cells in all measured samples was above 98%. The transformation efficiency
was calculated by counting the wells that contained actively proliferating B cells
4 weeks following infection.
Western blotting. For Western blotting, whole-cell extracts were prepared
from 106 cells with RIPA buffer (50 mM Tris-Cl, pH 6.8, 100 mM NaCl, 1%
Triton X-100, 0.1% sodium dodecyl sulfate) supplemented with complete mini
protease inhibitor cocktail (Roche Applied Sciences, Rotkreuz, Switzerland) and
1 mM sodium orthovanadate (Sigma-Aldrich) for 20 min on ice. For the detec-
tion of primary antibodies, we used horseradish peroxidase-labeled goat anti-
rabbit or anti-mouse antibodies from Pierce Biotechnology (Rockford, IL). Sig-
nal detection was performed by using the chemiluminescence substrate from
Pierce and scanning directly with the ChemiGenius imaging system (SynGene,
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Cambridge, United Kingdom), and signals were quantified with the GeneTools
3.1 image analysis software (SynGene).
ATP uptake assay. For ATP uptake, naı¨ve and memory B cells were seeded at
a density of 0.8  106 cells per ml in complete medium and were allowed to
proliferate for 24 h. ATP uptake was measured using the ViaLight bioassay kit
according to the instructions of the manufacturer (Lonzabiosciences, Basel,
Switzerland). As a reference, a standard curve was used to determine the abso-
lute cell numbers.
Statistical analyses. All experiments were carried out at least three times, and
representative results from the experiments are presented. Statistical analyses of
significance (P values) were based on a two-tailed paired t test. P values of0.05
were regarded as statistically significant.
RESULTS
Spinoculation with concentrated virus substantially in-
creases the proportion of primary B cells infected by EBV ex
vivo. We first established an infection protocol that would
provide a sufficient number of infected cells for analysis. Stan-
dard ex vivo inoculation protocols for primary human mono-
nuclear cells yield proportions of EBV-infected cells of up to
2% of total B cells (40). We thus adapted a protocol originally
designed to infect T cells with human immunodeficiency virus
type 1 that is based on low-speed centrifugation of cells in
human immunodeficiency virus type 1-containing supernatants
(spinoculation) (31). The low-speed centrifugation is thought
to facilitate virus binding to the cells, in contrast to pelleting of
the virus (31). To rapidly identify EBV-infected cells, we used
EBfaV-GFP, a recombinant EBV carrying a gene for EGFP
that replaces the LMP2 gene (39). The cytomegalovirus imme-
diate-early promoter is active in naı¨ve and memory B cells (22),
drives the constitutive expression of EGFP (40), and thus al-
lows the identification of all EBV-infected B cells as early as
24 h postinfection (40).
Following ex vivo inoculation of TMC with supernatants
from the EBV-producer cell line EBfaV-GFP, 1% of B cells
were infected at 48 h (Fig. 1A). Conventional inoculation using
supernatants from TPA-induced EBfaV-GFP infected up to
around 2% of B cells, even if the supernatants were concen-
trated 50-fold. Spinoculation with supernatants from non-
TPA-induced EBfaV-GFP infected around 6% of B cells when
the supernatants were concentrated 50-fold. The fraction of
infected TMC B cells could be further increased to 50% by
adding concentrated EBV-containing supernatants from TPA-
induced EBfaV-GFP (Fig. 1A to E). Similarly, ex vivo inocu-
lation of PBMC by spinoculation with TPA-induced and con-
centrated EBV led to 25-fold-higher infection frequencies than
inoculation with nonconcentrated EBV by conventional pro-
tocols (data not shown). Thus, spinoculation markedly in-
creased the fraction of infected B cells compared to that ob-
tained by conventional inoculation when either TPA-induced
or 50-fold-concentrated EBV was used.
Overall, the percentages of EBV-positive cells increased
from 1 to 30% of TMC and from 1 to 5% of PBMC. As
expected, B cells constituted a vast majority of the infected
cells (Fig. 1E).
EBV binding and the infection of B cells after spinoculation
depend on viral glycoproteins and their specific receptors. The
attachment of EBV to B cells is mediated by the direct inter-
action of EBV gp350/220 with cellular CD21, initiating recep-
tor-mediated endocytosis. After binding to CD21, EBV gp42
can interact with host HLA class II, leading to a conforma-
tional change in the viral glycoproteins and triggering fusion
with the host cell membrane (16, 38). To exclude nonspecific
EBV uptake during spinoculation (42, 43), we treated the
EBV-containing supernatants with antibodies against EBV
gp350/220, gp42, or both. In addition, we treated the target B
cells with antibodies against CD21, HLA class II, or both
before spinoculation (Fig. 1F and G). Cells were kept at 4°C
during spinoculation to inhibit EBV entry (30).
To quantify the efficiency of EBV binding to cells, we stained
cell-associated EBV with FITC-conjugated anti-EBV gp350/
220 antibodies and examined the cells by flow cytometry (Fig.
1F). Blocking EBV glycoprotein gp350/220 reduced the mean
efficiency of binding of spinoculated EBV to B cells to 65% in
a dose-dependent manner, as also observed earlier (26). Block-
ing the fusion-triggering EBV gp42 also resulted in a loss of
binding efficiency to 50% of that in controls, which may be due
to sterical hindrance or the loss of the gp350/220-CD21 inter-
action with the use of blocking antibodies to gp42. Simulta-
neous blocking of gp350/220 and gp42 reduced the mean bind-
ing efficiency of EBV to 22% of that in untreated samples,
showing that both attachment via gp350/220 and the subse-
quent interaction between gp42 and HLA class II are required
during the infection of cells by spinoculation (Fig. 1F). Block-
ing of the EBV receptor and coreceptor with anti-CD21 or
anti-HLA class II antibodies reduced EBV attachment to 10 to
15% of that in controls, and the simultaneous use of both
antibodies further reduced the mean level of cells showing
cell-associated EBV to 10% (Fig. 1F). The blocking of EBV
binding by anti-EBV gp350/220 did not influence the detection
of bound EBV by FITC–anti-EBV gp350/220 in comparisons
of EBV with free gp350/220 to EBV with blocked gp350/220
(Fig. 1F).
Similarly, blocking either gp350/220 or gp42 or both by
monoclonal antibodies dose dependently decreased the mean
levels of infected B cells from 40 to 50% to less than 5% (Fig.
1G). Blocking CD21, HLA class II, or both dose dependently
reduced the mean levels of infected B cells from 40 to 50% to
10 to 20% (Fig. 1G). These results indicate that spinoculation
does not bypass and change the requirements for the normal
binding and fusion of EBV with B cells.
Infecting lymphoid cells with EBV by spinoculation results
in a type III EBV gene mRNA expression pattern. Normally,
following the ex vivo infection of B cells by conventional inoc-
ulation, EBV undergoes the so-called type III program of
latency gene expression (33). To determine if spinoculation has
no aberrant effects on EBV gene expression after infection, we
compared the EBV mRNA expression profiles after infection
by spinoculation with those after infection by conventional
inoculation. Indeed, patterns of mRNA expression of EBV
latent genes, including EBNA1, EBNA2, LMP1, and LMP2, in
TMC and PBMC after conventional inoculation or spinocula-
tion with B95.8 EBfaV-GFP were similar (Fig. 2). Neverthe-
less, mRNA expression levels after spinoculation were 10- to
50-fold higher than those after conventional inoculation (Fig.
2). This increase is likely explained by the 25- to 50-fold en-
hancement in the proportion of infected cells following spino-
culation compared to that following conventional inoculation
(Fig. 1). Thus, EBV mRNA expression patterns were similar
irrespective of the inoculation protocol used. This finding sug-
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gested that spinoculation does not elicit an aberrant effect on
EBV gene expression.
As in subsequent experiments we planned to use the re-
porter virus EBfaV-GFP, we wished to determine if it behaved
as predicted. Previous studies have reported that the recombi-
nant B95.8EBfaV-GFP infects and transforms B cells as well as
the wild-type strain B95.8 (39). With the exception of LMP2
(which had lower mRNA expression levels after infection with
B95.8 EBfaV-GFP), infection with either virus gave the same
EBV mRNA expression profile. Although LMP2 is replaced by
EGFP in the reporter virus, there is still production of wild-
type virus in the producer cells (40), which we believed resulted
in the low LMP2 mRNA expression observed (Fig. 2D).
There is the possibility that the B-cell phenotype has an
effect on the EBV mRNA expression pattern, an important
feature in the context of the potential transformation ability.
FIG. 1. Spinoculation increases the total numbers of ex vivo EBV-infected B cells without affecting the specificity of infection. (A) Results of
inoculation and spinoculation of TMC with different concentrations of TPA-induced or uninduced cultures of the EBV strain B95.8EBfaV-GFP.
Cells were counterstained with R-phycoerythrin-labeled antibody against the B-cell surface marker CD19 and analyzed by flow cytometry 48 h after
inoculation. (B and C) Fluorescence microscopy of TMC 48 h after infection by inoculation with non-TPA-induced supernatants or by spino-
culation with 50-fold-concentrated supernatants from TPA-induced cultures of the EBV strain B95.8EBfaV-GFP. The percentages of EGFP cells
among the total number of cells are presented. (D and E) Flow cytometry quantification of EGFP cells 48 h after ex vivo inoculation with
non-TPA-induced EBV (D) or spinoculation with 50-fold-concentrated supernatants from TPA-induced cultures of the EBV strain B95.8EBfaV-
GFP (E). Cells were counterstained with R-phycoerythrin-labeled antibody directed against CD19. Values presented show the mean infection
rates of results from four independent experiments. (F) Binding of EBV to B cells. The efficiency of EBV binding to B cells was assessed using
50-fold-concentrated supernatants from TPA-induced B95.8EBfaV-GFP cells. The concentrated supernatants were treated with antibodies against
the EBV glycoprotein gp350/220, gp42, or both at serial dilutions or mock treated and used for ex vivo spinoculation of TMC at 4°C. Conversely,
TMC were treated with antibodies specifically targeting the two receptors required for EBV entry, CD21 and HLA class II, at serial dilutions (1:10,
1:100, 1:1,000, and 1:10,000) and then subjected to ex vivo spinoculation with 50-fold-concentrated supernatants from TPA-induced B95.8EBfaV-
GFP cells. The efficiency of the binding of EBV to B cells was determined by flow cytometry using FITC-labeled anti-EBV gp350/220 immediately
after spinoculation. (G) Infection of B cells with EBV. The EBV infection of B cells was quantified by flow cytometry to measure the EGFP
fluorescence intensity 24 h after spinoculation. Results from one independent experiment of two are shown.
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We therefore isolated naı¨ve and memory B cells from TMC at
24-h intervals during the first 7 days after spinoculation with
EBV and quantified EBV mRNA expression by quantitative
real-time PCR. The master regulator of all other EBV latent
genes, EBNA2, and the latent EBV genes EBNA1, EBNA3A,
EBNA3C, LMP1, and LMP2 showed almost identical patterns
of expression in naı¨ve and memory B cells (Fig. 3A to F). No
expression of the initiator and master regulator gene of lytic
infection, BZLF1, was detected in either B-cell subset (Fig.
3G). Also, the expression of lytic genes downstream of BZLF1
FIG. 2. Spinoculation and conventional inoculation of TMC and PBMC with EBV yielded similar mRNA expression patterns. TMC and PBMC
infection by spinoculation results in EBV gene mRNA expression patterns similar to those resulting from infection by conventional inoculation
using either the wild-type B95.8 EBV or B95.8EBfaV-GFP. Longitudinal EBV gene mRNA expression was assessed by specific quantitative
real-time PCR analysis. The mRNA expression of the genes encoding EBV nuclear antigen, EBNA2 (A) and EBNA1 (B), and those encoding the
EBV latent membrane proteins, LMP1 (C) and LMP2 (D), showed a sequential activation of EBNA2 and EBNA1, followed by LMP1 and LMP2.
The increased rate of infection of the cells with EBV after spinoculation was mirrored in the mRNA expression levels of EBV genes. The use of
the recombinant B95.8EBfaV-GFP EBV did not influence EBV gene mRNA expression compared to that in wild-type EBV. All EBV gene mRNA
expression data were normalized to the mRNA expression of the housekeeping gene for hydroxymethylbilane synthase (HMBS). Results shown
are from TMC from three donors and are expressed as means  standard errors of the means (SEM).
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was absent in naı¨ve and memory B cells (data not shown). This
finding is consistent with those in previously published reports
suggesting that EBV manifests primarily as a latent type III
infection in TMC after ex vivo infection and verifies that EBV
establishes latency in memory B cells in a fashion similar to
that in naı¨ve B cells (1). The isolation of naı¨ve B cells and that
of memory B cells before EBV infection showed comparable
results, thereby excluding possible effects of the cell isolation
on the EBV mRNA expression (data not shown).
Memory and naı¨ve B cells from tonsils, but not those from
peripheral blood, are equally susceptible to EBV infection.
CD21 and HLA-DR are absolutely required for the successful
infection of B cells with EBV. Among TMC and PBMC, naı¨ve
(CD19 CD27) and memory (CD19 CD27) B cells
showed similar levels of CD21 (Fig. 4A and B) and HLA-DR
(Fig. 4C and D) expression (summarized in Fig. 4E and F).
Conventional inoculation of TMC (Fig. 4G) or PBMC (Fig.
4H) resulted in very low levels of infected CD19 B cells
(naı¨ve B cells, 0.9%  0.1% and 0.5%  0.3%, respectively;
memory B cells, 0.02%  0.01% and 0.01%  0.01%, respec-
tively). Spinoculation increased the proportions of infected
naı¨ve and memory B cells dramatically compared to those
obtained by conventional inoculation. Strikingly, the propor-
tions of infected cells among the B-cell subsets of TMC were
rather similar (39.1%  2.2% EBV-positive memory B cells
versus 49.6%  16.7% EBV-positive naı¨ve B cells) (Fig. 4I).
However, among PBMC, the proportion of infected naı¨ve B
cells (69.2%  5.1%) was one-third higher than the propor-
tion of infected memory B cells (25.6%  4.8%; P  0.016)
(Fig. 4J).
Tonsillar memory B cells are more susceptible to EBV in-
fection after class switching than before. Ehlin-Henriksson et
al. reported that tonsillar B-cell subpopulations are equally
susceptible to EBV infection in vitro, irrespective of immuno-
globulin isotype expression (11). That study did not discrimi-
nate between naı¨ve (CD27) and IgM-expressing memory
(CD27) B cells (44). We therefore characterized in detail the
isotype expression in tonsillar memory (CD27) B cells sus-
ceptible to EBV infection. Thus, we isolated memory (CD27)
B cells from TMC and further segregated them into IgM-
negative and IgM-positive populations. Forty-eight hours after
inoculation with B95.8EBfaV-GFP, we analyzed the infection
frequencies among memory B cells expressing IgM, IgA, and
IgG (Fig. 5A). We found that IgM-expressing memory B cells
showed a significantly lower frequency of EBV infection than
memory B cells expressing IgA or IgG, suggesting that class-
switched memory B cells are more susceptible to EBV infec-
tion than their non-class-switched counterparts. We had to
exclude that EBV infection ex vivo alters the relative frequen-
cies of the B-cell subpopulations expressing IgM, IgA, or IgG.
To this end, we used isolated tonsillar memory (CD27) B
cells and infected them ex vivo with B95.8EBfaV-GFP. Forty-
eight hours after infection, mock-treated and EBV-exposed
memory B cells showed similar relative amounts of cells ex-
pressing IgM, IgA, or IgG (Fig. 5B).
We next asked whether, within the populations of EBV-
exposed cells, the relative distributions of isotype expression
among EBV-infected and non-EBV-infected cells were simi-
lar. Populations of EBV-infected cells showed a reduced fre-
quency of IgM-positive memory B cells compared to that in
populations of non-EBV-infected cells (P  0.003). This find-
ing again suggested that, among memory B cells, EBV prefer-
entially infects cells expressing IgA or IgG, i.e., memory B cells
after class switching. These observations are consistent with
FIG. 3. EBV gene expression patterns are similar in tonsillar mem-
ory and naı¨ve B cells after infection. (A to F) Comparison of the
longitudinal EBV gene mRNA expression patterns in tonsillar naı¨ve
and memory B cells after ex vivo infection by spinoculation. Both
memory and naı¨ve B cells expressed the EBV latency genes EBNA2
(A), EBNA1 (B), EBNA3A (C), EBNA3C (D), LMP1 (E), and LMP2
(F). (G) Neither B-cell subset initiated EBV lytic infection, as docu-
mented by the absence of mRNA expression of the EBV immediate-
lytic gene BZLF1. After spinoculation of TMC with EBV ex vivo,
memory and naı¨ve B cells were isolated with magnetic beads at differ-
ent times. The purity of the B-cell subsets was 98%. Results shown
are from TMC from three donors and are expressed as means SEM.
HMBS, hydroxymethylbilane synthase mRNA.
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FIG. 4. B-cell subsets from tonsils, but not those from peripheral blood, are equally susceptible to EBV infection. (A to D) Numbers of naı¨ve
and memory B cells expressing the EBV receptors CD21 and HLA-DR. Cells were stained with antibodies against CD19, CD27, CD21, and
HLA-DR, HLA-DP, and HLA-DQ. Flow cytometry plots are gated for CD19-expressing B cells and CD27-negative naı¨ve or CD27-positive
memory B cells. (E and F) Mean fluorescence intensities for CD21 and HLA-DR, HLA-DP, and HLA-DQ on naı¨ve and memory B cells from
tonsils and peripheral blood. (G and H) Hardly any infected memory B cells were detected among TMC (G) or PBMC (H) subjected to conven-
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the findings in a recent report showing that EBV is preferen-
tially excluded from the IgM-expressing memory B cells in vivo
(36).
Tonsillar memory B cells are transformed by EBV at lower
frequencies than tonsillar naı¨ve B cells. Tonsillar memory B
cells and naı¨ve B cells showed similar EBV mRNA expression
patterns after ex vivo infection; nevertheless, to test if their
EBV-associated growth transformation potentials were identi-
cal, we infected whole populations of TMC, in addition to
isolated tonsillar naı¨ve and memory B cells, with B95.8 by
spinoculation. We used wild-type B95.8 EBV in all transfor-
mation assays to exclude bias from the absence of LMP2 in the
recombinant virus (B95.8EBfaV-GFP). The cells were cul-
tured on an autologous feeder layer for 4 weeks to assess the
transformation of EBV-infected B cells. Whole TMC popula-
tions and isolated tonsillar naı¨ve B cells and tonsillar memory
B cells infected with EBV showed the typical formation of
cellular aggregates 48 h after spinoculation (data not shown),
and the number of aggregates and their sizes steadily increased
over the following 4 weeks (Fig. 6A to C) (29, 35). Conven-
tional inoculation of TMC resulted in a transformation effi-
ciency of around 60% when starting with 200 cells per well. In
contrast, the spinoculation of a whole TMC population and
isolated naı¨ve B cells and memory B cells increased the trans-
formation efficiency to more than 90% (Fig. 6B to D). Never-
theless, comparing the initial frequencies of infection of TMC
that we observed using conventional inoculation or spinocula-
tion with the transformation efficiencies suggested that using
the conventional transformation assay (35) led to a state of
initial saturation with EBV-infected B cells, which may lead to
underestimation of the transformation efficiency. Thus, we per-
formed a modified transformation assay, adding a limiting di-
lution of EBV-infected cells to a fixed number of B-cell-de-
pleted autologous feeder cells. The transformation efficiency
for naı¨ve B cells was significantly higher than the one for
memory B cells when cells were seeded at densities of 10 to 100
cells per well (Fig. 6E). Thus, memory B cells are transformed
by EBV with a lower efficiency than naı¨ve B cells. The micro-
graphs in Fig. 6 show naı¨ve and memory B cells at a cell density
optimized for growth transformation. As seen in Fig. 6E, with
the use of more than 100 naı¨ve or memory B cells per well for
transformation, no difference in transformation efficiency com-
pared to that obtained with 100 cells per well is detectable.
LCLs from memory B cells exhibit less apoptosis and slower
growth than LCLs from naı¨ve B cells. In vitro, naı¨ve B cells
exhibit more apoptosis than memory B cells (7). We hypothe-
sized that a change in apoptotic behavior after EBV infection
may explain the differences in growth transformation efficien-
cies between naı¨ve and memory B cells. As a marker for apop-
tosis, we analyzed the cleavage of PARP by Western blotting
tional EBV inoculation, which led to a very low rate of infection of the CD19 B cells. (I and J) Spinoculation led to a significant rise in the overall
infection rate of the B-cell population. Among TMC, the proportions of naı¨ve (CD19 CD27) and memory (CD19 CD27) B cells infected with
EBV were similar (I), but among PBMC, the proportion of memory cells infected with EBV was lower than that of naı¨ve B cells infected with EBV
(J). Data are expressed as means  SD of results from 10 independent experiments (A to F) and 3 independent experiments (G to J). P values
were calculated by paired Student’s t test.
FIG. 5. Class switch recombination renders tonsillar memory B cells more susceptible than naı¨ve B cells to EBV infection. (A) Infection
frequencies for isolated IgM-positive and IgM-negative tonsillar memory B cells. Memory B-cell populations that did not undergo class switch
recombination (IgM) showed significantly fewer infected cells 48 h postinoculation than their class-switched counterparts (IgG and IgA).
(B) Immunoglobulin isotype distribution among ex vivo EBV-infected tonsillar memory B cells 48 h postinoculation. The EGFP (EBV-infected)
population of the infected cells showed fewer IgM-positive cells than the corresponding EGFP (uninfected) population. The whole population
of infected cells showed no significant change in immunoglobulin composition compared to that of mock-infected controls. Results shown are from
TMC from four donors and are expressed as means  SEM. P values were calculated by paired Student’s t test.
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FIG. 6. Tonsillar memory B cells are less efficiently transformed by EBV than naı¨ve B cells. (A to C) Whole TMC populations, naı¨ve B cells, and
memory B cells isolated from EBV-seronegative donors showed the classical picture of cell aggregate formation and the outgrowth of transformed cells
24 weeks after ex vivo infection using B95.8EBfaV-GFP. (D) Transformation efficiencies after conventional EBV inoculation and EBV spinoculation
using the wild-type B95.8. TMC (2 105/well) infected with B95.8 were seeded into 96-well plates, and cells in wells showing proliferation after 4 weeks
and B-cell levels above 98% were considered to be transformed. For the transformation of different B-cell subsets, samples of 250 naı¨ve or memory B
cells were spinoculated using B95.8, mixed with 2  105 B-cell-depleted TMC, and seeded into each well in 96-well plates. After 4 weeks, cells in wells
showing proliferation and B-cell levels above 98% were considered to be transformed. conc., concentrated. (E) Transformation efficiencies of tonsillar
naı¨ve and memory B cells under conditions of limiting dilution. Naı¨ve and memory tonsillar B cells were inoculated with B95.8 supernatants by
spinoculation and were plated in 96-well plates together with an autologous feeder layer (2 105 cells/well). Cells in wells still showing growth and B-cell
levels above 98% after 4 weeks were regarded to be transformed. Results are means SD from three independent experiments. P values were calculated
by paired Student’s t test. TC50, 50% transformation concentration.
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(10). We also determined the numbers of naı¨ve and memory B
cells undergoing spontaneous apoptosis after EBV-associated
growth transformation into LCLs by staining with Annexin V
and 7-amino-actinomycin D (7-AAD). LCLs from naı¨ve B cells
showed twofold-higher levels of PARP cleavage than LCLs
from memory B cells (Fig. 7A). The frequency of apoptosis in
LCLs from naı¨ve B cells was around threefold higher than that
in LCLs from memory B cells, i.e., 13.1% 6.5% compared to
4.2%  2.8% (P  0.038) (Fig. 7B), when determined by
staining with Annexin V and 7-AAD. Thus, after EBV trans-
formation, naı¨ve B cells showed significantly more apoptosis
than did memory B cells. Therefore, these results alone could
not explain the somewhat lower transformation efficiency of
memory B cells than of naı¨ve B cells and led us to hypothesize
that the difference in transformation efficiency was linked to
unequal proliferation rates.
We assessed the proliferation characteristics of naı¨ve and
memory B cells before and after EBV-induced growth trans-
formation into LCLs by measuring the ATP uptake by the cells
over 24 h. ATP uptake in newly isolated memory B cells was
47%  15% that in their naı¨ve counterparts, implying that
memory B cells grow more slowly (data not shown). EBV-
transformed memory B cells showed 64%  9% of the ATP
uptake shown by EBV-transformed naı¨ve B cells (Fig. 7C).
These results indicate that naı¨ve and memory B cells retain
their distinct apoptotic and proliferation behaviors following
EBV transformation. That is, EBV-transformed memory B
cells exhibit a lower frequency of apoptosis and proliferate
more slowly than EBV-transformed naı¨ve B cells.
Next, we asked whether the observed differences in pro-
liferation were due to unequal EBV mRNA expression lev-
els. LCLs obtained after the infection of naı¨ve or memory B
cells showed similar patterns of mRNA expression of EBV
latent genes involved in B-cell transformation, with expres-
sion levels in naı¨ve cells being slightly higher (Fig. 7D). By
contrast, levels of BZLF1 mRNA in LCLs from memory B
FIG. 7. Naı¨ve and memory B cells retain their distinct apoptosis and proliferation characteristics after EBV-induced transformation. (A) Naı¨ve
and memory B cells show different apoptotic behaviors after EBV growth transformation. LCLs from naı¨ve B cells are more susceptible to
apoptosis than the autologous memory B cells, as assessed by Western blotting to detect the cleavage of PARP. Numbers below the blot indicate
the level of PARP cleavage (n-fold) as normalized to actin and to PARP cleavage in memory B-cell LCLs. (B) LCLs from memory B cells show
a lower proportion of cells undergoing apoptosis than LCLs from naı¨ve B cells as measured by staining with Annexin V and 7-AAD. (C) LCLs
from memory B cells as assessed by ATP uptake. (D) LCLs from naı¨ve B cells and those from memory B cells express mRNA of the same set of
EBV latency genes at equal levels, as determined by real-time PCR analysis. (E) EBV-transformed naı¨ve B cells show a higher frequency of cells
undergoing lytic EBV reactivation than EBV-transformed memory B cells, as measured by the mRNA expression of BZLF1. HMBS, hydroxy-
methylbilane synthase mRNA.
VOL. 82, 2008 EBV SUSCEPTIBILITY OF B-CELL SUBSETS 4409
cells were significantly lower than those in LCLs from naı¨ve
B cells (Fig. 7E).
Compared to EBV-transformed naı¨ve B cells, EBV-trans-
formed memory B cells exhibit reduced apoptosis and lytic
EBV gene expression. However, we believe that the slower
proliferation of EBV-transformed memory B cells likely ex-
plains the lower EBV transformation efficiency of these cells in
the dilution series experiments.
DISCUSSION
In this work, we aimed to assess the efficiencies of infection
of distinct B-cell subsets from different lymphoid compart-
ments and to compare the transformation behaviors of B-cell
subsets infected ex vivo with EBV. Indeed, we found that
tonsillar naı¨ve and memory B cells were equally susceptible to
ex vivo EBV infection but that peripheral blood memory B
cells were less susceptible than naı¨ve B cells. These data indi-
cate that the tissue origin of memory B cells impacts the sus-
ceptibility to EBV infection. Moreover, among tonsillar mem-
ory B cells, the subset expressing IgM was less susceptible to
EBV infection than the subsets expressing IgA or IgG, sug-
gesting that class switching also impacts the susceptibility to
EBV infection. Finally, even though tonsillar naı¨ve and mem-
ory B cells displayed very similar patterns of EBV gene expres-
sion that is crucial to establish B-cell transformation, memory
B cells showed significantly lower EBV-associated transforma-
tion efficiency than naı¨ve B cells. This finding may be due to the
inherently higher proliferation rates of naı¨ve B cells than of
memory B cells. Our findings, thus, reveal that the susceptibil-
ities of B-cell subsets to EBV infection and their transforma-
tion capacities are not uniform and suggest that EBV exploits
the status of differentiation and the compartment of origin of
B cells to optimize the establishment of latency in the host.
Conventional protocols for EBV infection inoculate target
cells with supernatant from EBV-positive cell lines that have
been driven into lytic infection by mitogens or by the cross-
linking of the B-cell receptor (9, 27). Such inoculation results
in EBV infection of less than 2% of primary B cells (40). This
low proportion hampers the clear dissection of what subsets of
B cells are susceptible to EBV (39). To investigate the suscep-
tibilities of distinct B-cell subsets, we needed to reach a higher
infectivity rate. By using spinoculation with concentrated EBV,
we increased the proportion of CD19 B cells infected with
EBV to more than 50% at 48 h after inoculation. The entry
process of EBV was almost completely inhibited when anti-
bodies against the EBV envelope gp350/220 and gp42 or the
B-cell receptors CD21 and HLA class II were added before
spinoculation. This result clearly indicates that the increased
infection frequency resulted from specific virus entry through
the known EBV receptors and not from an unspecific uptake.
Thus, the ex vivo EBV infection of B cells by spinoculation
likely mimics the natural B-cell infection pathway and thus
enabled us to study EBV infection in B-cell subsets from pri-
mary cells. Importantly, by using primary cells exclusively from
EBV-negative individuals, we excluded bias from preexisting
EBV-specific immunity or the necessity to apply immunosup-
pressive drugs in vitro in transformation experiments.
Indeed, using this optimized infection protocol, we found
that memory B cells isolated from tonsils are susceptible to ex
vivo EBV infection at frequencies similar to those of their
naı¨ve counterparts. This observation is in agreement with our
finding of similar densities of the receptors for EBV (i.e.,
CD21 and HLA-DR) on tonsillar naı¨ve and memory B cells, as
defined by the expression of CD27. In contrast, among PBMC,
the proportion of infected memory B cells corresponded to
only one-third of that of infected naı¨ve B cells (Fig. 2). Strik-
ingly, the densities of receptors CD21 and HLA-DR on naı¨ve
and memory B cells among PBMC were similar. This obser-
vation of a tissue origin-dependent susceptibility rate of mem-
ory B cells was unexpected. We speculate that the priming of
naı¨ve B cells at different anatomic sites results in the distinct
susceptibility of memory B cells to EBV infection and that
EBV succeeds in optimally exploiting unknown cellular factors
present exclusively in tonsillar memory B cells. Notably, the
tonsils are the portal of entry for EBV. Our finding that naı¨ve
B cells from peripheral blood were susceptible to EBV ex vivo
contrasts with the absence of EBV-infected naı¨ve B cells in
peripheral blood in vivo (17). Likely explanations for this dis-
crepancy are that naı¨ve B cells infected at the portal of entry
for EBV are too short-lived to gain access to the circulation as
long as they do not differentiate into long-lived memory B cells
and that EBV virions or productively infected memory B cells
are hardly found in the peripheral blood (2).
B cells expressing CD27 correspond to functional memory B
cells, i.e., B cells having completed antigen-driven selection
and differentiation and thus exiting or having left germinal
centers (41). Our data, which show that EBV infects CD27
tonsillar B cells and CD27 tonsillar B cells with equal effi-
ciencies, suggest that the degree of susceptibility to EBV in-
fection is retained in B cells exiting the germinal center. We
propose that functional memory B cells represent one direct
target of EBV at its natural portal of entry in vivo. The infec-
tion of memory B cells in addition to naı¨ve B cells at the portal
of entry would provide EBV with an additional important
biological advantage to increase the pool of infected B cells
and thus secure persistence in the host. The targeting of func-
tional memory B cells by EBV, either directly or indirectly via
the infection of naı¨ve B cells subsequently driven through a
germinal-center reaction by the virus (37), holds the advantage
that the EBV-infected B cell is subjected to proliferation and
differentiation signals from cognate antigens when homing
back to the tonsils. Tonsillar memory B cells are certainly more
frequently exposed to antigens than, e.g., memory B cells from
lymph nodes draining normally sterile body tissues. This sce-
nario in turn would ensure that latent EBV is handed over to
progeny cells. In addition, following the differentiation of the
EBV-infected memory B cells into plasma cells, which repre-
sent the site of lytic replication (25), EBV could gain access to
other susceptible B cells or epithelial cells and, via saliva, to
susceptible new hosts.
Our data clearly demonstrate that among CD27 memory B
cells, those expressing IgA or IgG are significantly more sus-
ceptible to EBV infection than those expressing IgM. This fact
suggests that if EBV uses tonsillar memory B cells as a direct
target, the virus preferentially accesses isotype-switched cells.
In agreement with our observations, the vast majority of EBV
DNA in peripheral blood cells from EBV carriers has been
detected in surface-IgA-positive B cells (12). Moreover, recent
work on peripheral blood B cells isolated from patients with
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infectious mononucleosis found that EBV-infected cells were
preferentially excluded from the IgM isotype in the CD27
memory B-cell pool (36). Based on this finding and on the
presence of more frequent somatic hypermutations in EBV-
infected than in non-EBV-infected CD27 B cells, the authors
of the study concluded that EBV impacts the infected cells
themselves by promoting their germinal-center reaction with
isotype switching (36). Thus, it appears that EBV infects B
cells at different differentiation stages.
A remarkable finding of this work is that tonsillar memory B
cells manifest significantly lower EBV-induced transformation
efficiency than their naı¨ve counterparts. The infection of B cells
with EBV in vitro is well-known to result in the expression of
the so-called latency III viral gene expression program. This
program is characterized by the expression of six nuclear an-
tigens (EBNA1 to EBNA6), LMP1, and LMP2 (33), which are
required for establishing EBV latency and EBV-induced
growth transformation and immortalization (13). Both tonsil-
lar B-cell subsets expressed mRNA of EBNA2, the master
regulator of latency, and mRNAs of EBNA1, LMP1 and LMP2,
and EBNA3A and EBNA3C, which are also important for EBV
growth transformation (1) following infection with EBV in
vitro. Importantly, the mRNA expression levels of the latency
genes involved in cellular transformation were similar in naı¨ve
and memory B cells, suggesting what would let us expect sim-
ilar EBV-induced transformation efficiencies for the two B-cell
subsets. The higher apoptosis frequency and higher mRNA
expression levels of BZLF1 in transformed naı¨ve than in mem-
ory B cells, indicating greater initiation of spontaneous EBV
lytic infection in LCLs from naı¨ve B cells, would rather suggest
a lower transformation rate of naı¨ve B cells, which is, however,
not the case. Therefore, qualitative and quantitative EBV gene
mRNA expression patterns alone do not allow firm conclu-
sions on the host-pathogen interactions.
Another explanation for the distinct transformation capaci-
ties of B-cell subsets may be a difference in cell proliferation
rates. In fact, we found that the lower transformation efficiency
of memory B cells was paralleled by their reduced rate of
proliferation compared to that of naı¨ve B cells. Importantly,
the proliferation rates of these two B-cell subsets differed be-
fore and after EBV-induced transformation. This result sug-
gests that infection with EBV does not significantly alter the
proliferation characteristics associated with B-cell differentia-
tion.
In conclusion, our data demonstrate that spinoculation en-
hances EBV infection without bypassing the requirements for
the normal binding of EBV to or the entry of EBV into B cells
and, therefore, offers a highly valuable in vitro tool to study
EBV infection, host-pathogen interactions, and pathogenesis.
This tool allowed the first-time quantification of striking dif-
ferences in susceptibility to EBV infection and EBV-induced
transformation efficiency between B-cell subsets. These differ-
ences were dependent on the tissues of origin and the differ-
entiation statuses of the cells, suggesting that EBV exploits the
characteristics of B-cell subsets to optimize the establishment
of latent infection.
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